Synairgen Past Earnings Performance
Past criteria checks 0/6
Synairgen's earnings have been declining at an average annual rate of -19.6%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 96.4% per year.
Key information
-19.6%
Earnings growth rate
-12.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -96.4% |
| Return on equity | -66.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Synairgen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 4 | 7 |
| 30 Sep 23 | 0 | -9 | 4 | 7 |
| 30 Jun 23 | 0 | -10 | 5 | 7 |
| 31 Mar 23 | 0 | -14 | 5 | 11 |
| 31 Dec 22 | 0 | -18 | 5 | 15 |
| 30 Sep 22 | 0 | -23 | 6 | 21 |
| 30 Jun 22 | 0 | -28 | 6 | 27 |
| 31 Mar 22 | 0 | -38 | 5 | 40 |
| 31 Dec 21 | 0 | -49 | 5 | 53 |
| 30 Sep 21 | 0 | -46 | 4 | 50 |
| 30 Jun 21 | 0 | -43 | 4 | 48 |
| 31 Mar 21 | 0 | -28 | 3 | 32 |
| 31 Dec 20 | 0 | -14 | 2 | 15 |
| 30 Sep 20 | 0 | -10 | 2 | 11 |
| 30 Jun 20 | 0 | -6 | 1 | 6 |
| 31 Mar 20 | 0 | -5 | 1 | 5 |
| 31 Dec 19 | 0 | -4 | 1 | 3 |
| 30 Sep 19 | 0 | -4 | 1 | 3 |
| 30 Jun 19 | 0 | -4 | 1 | 4 |
| 31 Mar 19 | 0 | -3 | 1 | 3 |
| 31 Dec 18 | 0 | -3 | 1 | 3 |
| 30 Sep 18 | 3 | -1 | 1 | 3 |
| 30 Jun 18 | 5 | 2 | 1 | 2 |
| 31 Mar 18 | 5 | 2 | 1 | 2 |
| 31 Dec 17 | 5 | 2 | 1 | 2 |
| 30 Sep 17 | 3 | 0 | 1 | 2 |
| 30 Jun 17 | 0 | -3 | 1 | 2 |
| 31 Mar 17 | 0 | -3 | 1 | 2 |
| 31 Dec 16 | 0 | -3 | 1 | 2 |
| 30 Sep 16 | 0 | -3 | 1 | 2 |
| 30 Jun 16 | 0 | -3 | 1 | 2 |
| 31 Mar 16 | 0 | -2 | 1 | 2 |
| 31 Dec 15 | 0 | -2 | 1 | 1 |
| 30 Sep 15 | 0 | -2 | 1 | 1 |
| 30 Jun 15 | 0 | -2 | 1 | 1 |
| 31 Mar 15 | 2 | 0 | 1 | 1 |
| 31 Dec 14 | 4 | 1 | 2 | 2 |
| 30 Sep 14 | 4 | 1 | 2 | 2 |
| 30 Jun 14 | 4 | 1 | 2 | 2 |
| 31 Mar 14 | 2 | -1 | 1 | 2 |
| 31 Dec 13 | 0 | -2 | 1 | 1 |
Quality Earnings: OMY is currently unprofitable.
Growing Profit Margin: OMY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OMY is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare OMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OMY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: OMY has a negative Return on Equity (-66.43%), as it is currently unprofitable.